Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Randomized, Double-blind, 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183 is registered in ClinicalTrials.gov with Apollo Therapeutics Ltd as lead sponsor.

NCT NCT06436183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06436183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Randomized, Double-blind, 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Lead sponsor
Apollo Therapeutics Ltd
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2024
Completion date
August 12, 2025
Enrollment
62 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

atopic, atopic dermatitis, dermatitis, dermatologic disease, eczema, eczema atopic dermatitis, eczema, atopic